530 related articles for article (PubMed ID: 24695685)
1. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
Iwama S; De Remigis A; Callahan MK; Slovin SF; Wolchok JD; Caturegli P
Sci Transl Med; 2014 Apr; 6(230):230ra45. PubMed ID: 24695685
[TBL] [Abstract][Full Text] [Related]
2. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.
Caturegli P; Di Dalmazi G; Lombardi M; Grosso F; Larman HB; Larman T; Taverna G; Cosottini M; Lupi I
Am J Pathol; 2016 Dec; 186(12):3225-3235. PubMed ID: 27750046
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
[TBL] [Abstract][Full Text] [Related]
5. [Hypophysitis: increasingly complex clinicopathological spectrum!].
Allix I; Rohmer V
Ann Endocrinol (Paris); 2012 Oct; 73 Suppl 1():S17-25. PubMed ID: 23089377
[TBL] [Abstract][Full Text] [Related]
6. [Current update on hypophysitis].
Allix I; Rohmer V
Rev Med Interne; 2014 Dec; 35(12):815-22. PubMed ID: 25109447
[TBL] [Abstract][Full Text] [Related]
7. Recovery from lymphocytic hypophysitis associated with painless thyroiditis: clinical implications of circulating antipituitary antibodies.
Ozawa Y; Shishiba Y
Acta Endocrinol (Copenh); 1993 Jun; 128(6):493-8. PubMed ID: 8393255
[TBL] [Abstract][Full Text] [Related]
8. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
Kaehler KC; Egberts F; Lorigan P; Hauschild A
Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
[TBL] [Abstract][Full Text] [Related]
9. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis.
Heaney AP; Sumerel B; Rajalingam R; Bergsneider M; Yong WH; Liau LM
J Clin Endocrinol Metab; 2015 Nov; 100(11):4092-7. PubMed ID: 26317559
[TBL] [Abstract][Full Text] [Related]
10. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses.
Torino F; Barnabei A; Paragliola RM; Marchetti P; Salvatori R; Corsello SM
Eur J Endocrinol; 2013 Dec; 169(6):R153-64. PubMed ID: 24001893
[TBL] [Abstract][Full Text] [Related]
11. Anti-pituitary antibodies against corticotrophs in IgG4-related hypophysitis.
Iwata N; Iwama S; Sugimura Y; Yasuda Y; Nakashima K; Takeuchi S; Hagiwara D; Ito Y; Suga H; Goto M; Banno R; Caturegli P; Koike T; Oshida Y; Arima H
Pituitary; 2017 Jun; 20(3):301-310. PubMed ID: 27896569
[TBL] [Abstract][Full Text] [Related]
12. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
Dillard T; Yedinak CG; Alumkal J; Fleseriu M
Pituitary; 2010; 13(1):29-38. PubMed ID: 19639414
[TBL] [Abstract][Full Text] [Related]
13. Preparation of mouse pituitary immunogen for the induction of experimental autoimmune hypophysitis.
Tzou SC; Landek-Salgado MA; Kimura H; Caturegli P
J Vis Exp; 2010 Dec; (46):. PubMed ID: 21206466
[TBL] [Abstract][Full Text] [Related]
14. [Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors].
Iwama S; Arima H
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):90-94. PubMed ID: 28603206
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
[TBL] [Abstract][Full Text] [Related]
16. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
17. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
18. Detection of autoantibodies against the pituitary-specific proteins in patients with lymphocytic hypophysitis.
Tanaka S; Tatsumi KI; Kimura M; Takano T; Murakami Y; Takao T; Hashimoto K; Kato Y; Amino N
Eur J Endocrinol; 2002 Dec; 147(6):767-75. PubMed ID: 12457452
[TBL] [Abstract][Full Text] [Related]
19. Immunopathology of primary hypophysitis: implications for pathogenesis.
Gutenberg A; Buslei R; Fahlbusch R; Buchfelder M; Brück W
Am J Surg Pathol; 2005 Mar; 29(3):329-38. PubMed ID: 15725801
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune hypophysitis: new developments.
Takahashi Y
Handb Clin Neurol; 2014; 124():417-22. PubMed ID: 25248604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
